Generic Name and Formulations:
Aprepitant 130mg/18mL; emulsion for IV infusion after dilution; contains egg lecithin, ethanol.
Indications for CINVANTI:
In combination with other antiemetic agents to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic cancer chemotherapy, including high-dose cisplatin.
Limitations Of use:
Not studied for treating established nausea and vomiting.
Give with dexamethasone and 5-HT3 antagonist (see full labeling). Administer approx. 30mins prior to chemotherapy. Moderately emetogenic: 100mg IV over 30mins on Day 1, then oral aprepitant 80mg on Days 2 and 3. Highly emetogenic: 130mg IV over 30mins on Day 1.
Severe hepatic impairment. Monitor for hypersensitivity reactions; discontinue and treat appropriately if occur; do not reinitiate if symptoms develop with first-time use. Pregnancy: not recommended. Nursing mothers.
Substance P/NK1 receptor antagonist.
See Contraindications. Monitor concomitant CYP3A4 substrates, including chemotherapy agents (eg, ifosfamide, vinblastine, vincristine). Avoid concomitant moderate-to-strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir, diltiazem) or strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin). Potentiates dexamethasone (reduce its oral dose by 50%), methylprednisolone (reduce its IV dose by 25% and its oral dose by 50%), midazolam, alprazolam, triazolam. May antagonize warfarin (closely monitor INR for 2 weeks after starting each cycle), other CYP2C9 substrates, oral contraceptives (use alternative or backup methods during and for 1 month after last dose).
Headache, fatigue, eructation, infusion-site reactions; anaphylaxis.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Predicting Pain Chronicization After Spine Surgery
- Chronic Low Back Pain Levels Vary Between Sex and Race
- FDA Approval of Medication With a Digital Monitoring System: Major Breakthrough or "Brave New World"?
- Errors in Clinical Notes Generated by Speech Recognition Are Not Uncommon
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?